home / stock / oscr / oscr quote
Last: | $16.59 |
---|---|
Change Percent: | -0.06% |
Open: | $15.88 |
Close: | $16.59 |
High: | $16.7 |
Low: | $15.8625 |
Volume: | 2,469,575 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$16.59 | $15.88 | $16.59 | $16.7 | $15.8625 | 2,469,575 | 07-02-2024 |
$15.87 | $15.85 | $15.87 | $16.14 | $15.37 | 3,773,356 | 07-01-2024 |
$15.82 | $17.8 | $15.82 | $17.8 | $15.15 | 17,306,347 | 06-28-2024 |
$17.65 | $17.7 | $17.65 | $18.09 | $17.53 | 2,604,083 | 06-27-2024 |
$17.92 | $17.8 | $17.92 | $17.93 | $17.33 | 2,274,636 | 06-26-2024 |
$17.64 | $17.89 | $17.64 | $18.06 | $17.44 | 3,217,414 | 06-25-2024 |
$17.75 | $18.07 | $17.75 | $18.39 | $17.66 | 2,142,290 | 06-24-2024 |
$18.06 | $17.93 | $18.06 | $18.19 | $17.14 | 4,548,385 | 06-21-2024 |
$18.04 | $19.42 | $18.04 | $19.42 | $18.02 | 3,157,651 | 06-20-2024 |
$19.23 | $18.86 | $19.23 | $19.49 | $18.85 | 2,594,792 | 06-19-2024 |
$19.23 | $18.86 | $19.23 | $19.49 | $18.85 | 2,594,792 | 06-18-2024 |
$18.8 | $18.95 | $18.8 | $19.36 | $18.58 | 1,824,532 | 06-17-2024 |
$19 | $18.87 | $19 | $19.329 | $18.72 | 2,016,985 | 06-14-2024 |
$19 | $19.06 | $19 | $19.22 | $18.24 | 2,868,621 | 06-13-2024 |
$19.06 | $20.6 | $19.06 | $20.94 | $18.79 | 3,380,911 | 06-12-2024 |
$20.01 | $20.82 | $20.01 | $21.17 | $19.95 | 4,010,320 | 06-11-2024 |
$20.51 | $19.8 | $20.51 | $20.7 | $19.751 | 5,438,597 | 06-10-2024 |
$19.32 | $19.24 | $19.32 | $19.44 | $17.15 | 7,020,407 | 06-07-2024 |
$19.5 | $19.71 | $19.5 | $19.8899 | $18.75 | 3,059,697 | 06-06-2024 |
$19.7 | $19.03 | $19.7 | $19.9 | $18.85 | 3,548,604 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Oscar Health Inc. Class A Company Name:
OSCR Stock Symbol:
NYSE Market:
Oscar Health Inc. Class A Website:
2024-06-25 17:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for OSCR on June 25, 2024 04:13PM ET. OSCR was trading at $17.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 2 - ...